

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**INSIDE INFORMATION
PLACING OF EXISTING SHARES
BY A SUBSTANTIAL SHAREHOLDER**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provision under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

PLACING AGREEMENT

The board of directors (the “**Board**”) of the Company was informed by Mr. Tse Ping (“**Mr. Tse**”) (Chief Executive Officer, an executive director and a substantial shareholder of the Company) that on 21 April 2020, Mr. Tse as vendor entered into a placing agreement (the “**Placing Agreement**”) with third parties independent from the Company acting as managers to procure placees to purchase for 200,000,000 shares of the Company (“**Placing Shares**”) at a placing price of HK\$11.35 per Placing Share (the “**Placing**”). Completion of the Placing (the “**Completion**”) is currently expected to take place on 23 April 2020.

MR. TSE'S SHAREHOLDING BEFORE AND AFTER COMPLETION

As at the date of this announcement, Mr. Tse beneficially owns 1,383,790,083 shares of the Company (“**Shares**”), representing approximately 11.00% of the issued share capital of the Company, comprising 210,600,000 Shares directly held by Mr. Tse and 1,173,190,083 Shares indirectly held through Validated Profits Limited (“**Validated Profits**”), a company wholly-owned by Mr. Tse. Upon Completion, assuming that all of the Placing Shares are to be placed out, and that there is no change in the issued share capital of the Company from the date of this announcement to Completion, the number of Shares beneficially owned by Mr. Tse will decrease to 1,183,790,083 Shares, representing approximately 9.40% of the issued share capital of the Company, comprising 10,600,000 Shares directly held by Mr. Tse and 1,173,190,083 Shares indirectly held through Validated Profits.

The Board does not expect the Placing to have any impact on the business or operations of the Company and its subsidiaries. The composition of the Board remains unchanged and the day-to-day operation and management of the Company will reside with the current management team of the Company, which will continue to be led by Mr. Tse Ping and his family members, comprising Ms. Cheng Cheung Ling, Ms. Tse, Theresa Y Y and Mr. Tse, Eric S Y.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 21 April 2020

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.